Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Harold Bernstein, President of Research and Development and Chief Medical Officer at Maze Therapeutics, Inc. (NASDAQ:MAZE), ...
Yahoo Finance

Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Motley Fool

Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.

Maze Therapeutics develops small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity; lead assets include MZE829 (APOL1 inhibitor, Phase II) and MZE782 ...
Nasdaq

Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT) been one of those stocks this ...